Piramal Pharma (BOM:543635) Debt-to-Asset : 0.31 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma Debt-to-Asset?

Piramal Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹21,084 Mil. Piramal Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹26,017 Mil. Piramal Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ₹153,118 Mil. Piramal Pharma's debt to asset for the quarter that ended in Mar. 2024 was 0.31.

Piramal Pharma Debt-to-Asset Historical Data

The historical data trend for Piramal Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma Debt-to-Asset Chart

Piramal Pharma Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Debt-to-Asset

0.03

0.32

0.39

0.31

Piramal Pharma Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial							0.39	-	0.31	-	0.31

Competitive Comparison of Piramal Pharma's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Piramal Pharma's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Piramal Pharma's Debt-to-Asset falls into.

Piramal Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Piramal Pharma's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(21084.2	+	26017.4)	/	153118.1
	=	0.31

Piramal Pharma's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(21084.2	+	26017.4)	/	153118.1
	=	0.31

Piramal Pharma (BOM:543635) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Piramal Pharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Piramal Pharma (BOM:543635) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (BOM:543635) » Definitions » Debt-to-Asset

Traded in Other Exchanges

PPLPHARMA:India

Address

Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, MH, IND, 400070

Website

https://www.piramal.com

Piramal Pharma Ltd offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. It includes integrated contract development and manufacturing organization business, complex hospital generics business, and India consumer healthcare business, selling over-the-counter products in India.

Piramal Pharma (BOM:543635) Headlines

No Headlines